Neuroscientists at Georgetown University Medical Center say they have developed and tested an agent that reduces the buildup of toxic proteins in animal models of both Parkinson's and Alzheimer's diseases, and improves cognitive ...
Oct 23, 2019
0
473
The introduction of the drug imatinib in 2001 revolutionized the treatment of a type of cancer called chronic myelogenous leukemia. In more than 80 percent of people with CML who received the drug, the disease went into complete ...
Oct 16, 2019
0
1021
No matter the pathogen—virus, bacterium or fungus—many "pick a specific type of lock" on the surface of cells, which allows the microbe to break and enter into the inner sanctum of the host's genome.
DDR1 is a receptor tyrosine kinase (RTK)—a cell surface receptor—that regulates multiple functions including the maintenance of the normal structure of tissues, but which also contributes to pathological conditions including ...
Aug 9, 2019
0
3
Patients with chronic myeloid leukemia can be treated with tyrosine kinase inhibitors. While these effective drugs lead to deep remission and prolonged survival, primitive leukemia stem cells resist elimination during the ...
Jun 11, 2019
0
13
An important class of drug used to treat cancer patients could be used to treat brain aneurysms, according to new research published this week.
May 17, 2019
0
154
(HealthDay)—The selective Bruton's tyrosine kinase (BTK) inhibitor evobrutinib at a dose of 75 mg once daily is associated with fewer enhancing lesions during weeks 12 through 24 among patients with relapsing multiple sclerosis, ...
May 14, 2019
0
2
There are more than 100 mutations of the protein behind the deadly brain cancer, glioblastoma, however an international research team has discovered something these mutations have in common. The new understanding could lead ...
Apr 30, 2019
0
1
(HealthDay)—For patients with chronic myeloid leukemia (CML), tyrosine kinase inhibitor (TKI) therapy can be safely discontinued and yields high rates of treatment-free remission (TFR), according to a study published online ...
Apr 16, 2019
0
1
Relapse of disease following conventional treatments remains one of the central problems in cancer management, yet few therapeutic agents targeting drug resistance and tolerance exist. New research conducted at the Cancer ...
Apr 8, 2019
0
91
